Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi ...

Over the last couple of months, senior leaders from across the Coloplast Group have worked together to finalise the new Coloplast Group strategy, which will be communicated internally and externally ...

Idorsia Ltd (SIX: IDIA) announces the end results of the repurchase offer for its outstanding CHF 204 *  million convertible bonds maturing in 2025 (CB 2025; ISIN CH0426820350), and CHF 600 million ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

To help close this prevention gap in Florida, a new health platform, WePrevent.org, launched today with a mission to shift ...

Photo: Founder and Chief Dentist Dr. Mehmet İşlek of Attelia Dental Clinic receiving the Quality Choice Prize 2025 award.

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel ...

After extensive negotiations, Opthea has reached a binding agreement with the DFA Investors to terminate the DFA. As part of the settlement arrangements, all parties have entered into an agreement of ...

Mowad-Nassar will serve as an independent director and has been appointed to the Compensation and Leadership Development Committee. She will stand for reelection with the rest of Resmed’s board ...

(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, PhD, to the ...

The stock options have a ten-year term and exercise prices ranging from $2.11 to $2.04 per share, which is equal to the closing price of Vor Bio’s common stock on the respective grant dates of the ...